Yahoo
TSXV - Delayed Quote CAD

Hemostemix Inc. (HEM.V)

0.0600 0.0000 (0.00%)
At close: October 29 at 3:56:07 PM EDT
Chart Range Bar
Loading chart for HEM.V
  • Previous Close 0.0600
  • Open 0.0500
  • Bid 0.0500 x --
  • Ask 0.0600 x --
  • Day's Range 0.0500 - 0.0600
  • 52 Week Range 0.0400 - 0.1100
  • Volume 95,200
  • Avg. Volume 26,498
  • Market Cap (intraday) 12.686M
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date (est.) Nov 27, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

hemostemix.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

HEM.V
29.41%
S&P/TSX Composite index (^GSPTSE)
11.78%

1-Year Return

HEM.V
36.84%
S&P/TSX Composite index (^GSPTSE)
18.03%

3-Year Return

HEM.V
29.41%
S&P/TSX Composite index (^GSPTSE)
88.90%

5-Year Return

HEM.V
68.42%
S&P/TSX Composite index (^GSPTSE)
69.32%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -534.31%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -4.62M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    196.46k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.45M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: